These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21312292)

  • 1. Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.
    Riahi F; Tehrani-Doost M; Shahrivar Z; Alaghband-Rad J
    Hum Psychopharmacol; 2010 Nov; 25(7-8):570-6. PubMed ID: 21312292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Ratner S; Laor N; Bronstein Y; Weizman A; Toren P
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):428-33. PubMed ID: 15843764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
    Spivak B; Strous RD; Shaked G; Shabash E; Kotler M; Weizman A
    J Clin Psychopharmacol; 2006 Apr; 26(2):152-6. PubMed ID: 16633143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
    Spencer T; Biederman J; Wilens T; Doyle R; Surman C; Prince J; Mick E; Aleardi M; Herzig K; Faraone S
    Biol Psychiatry; 2005 Mar; 57(5):456-63. PubMed ID: 15737659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine for attention deficit/hyperactivity disorder.
    Garces K
    Issues Emerg Health Technol; 2003 May; (46):1-4. PubMed ID: 12751480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.
    Young JL; Sarkis E; Qiao M; Wietecha L
    Clin Neuropharmacol; 2011; 34(2):51-60. PubMed ID: 21406998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.
    Wilens TE; Haight BR; Horrigan JP; Hudziak JJ; Rosenthal NE; Connor DF; Hampton KD; Richard NE; Modell JG
    Biol Psychiatry; 2005 Apr; 57(7):793-801. PubMed ID: 15820237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: an open-label trial.
    Golubchik P; Sever J; Weizman A
    Clin Neuropharmacol; 2013; 36(2):37-41. PubMed ID: 23503544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study.
    Biederman J; Mick E; Faraone S; Hammerness P; Surman C; Harpold T; Dougherty M; Aleardi M; Spencer T
    J Clin Psychopharmacol; 2006 Apr; 26(2):163-6. PubMed ID: 16633145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
    Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
    Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
    Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.
    Kahbazi M; Ghoreishi A; Rahiminejad F; Mohammadi MR; Kamalipour A; Akhondzadeh S
    Psychiatry Res; 2009 Aug; 168(3):234-7. PubMed ID: 19439364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Zarinara AR; Mohammadi MR; Hazrati N; Tabrizi M; Rezazadeh SA; Rezaie F; Akhondzadeh S
    Hum Psychopharmacol; 2010 Nov; 25(7-8):530-5. PubMed ID: 20860068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV; Glatt SJ
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.